Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab immediately reversed the anticoagulant effect of dabigatran (Pradaxa) in patients requiring urgent anticoagulant reversal. No safety concerns relating to idarucizumab were identified.Ā The results have been simultaneously published in theĀ New England Journal of Medicine (NEJM)Ā and presented at the International Society of Thrombosis and Haemostasis 2015 Congress in Toronto, Canada.

Safety accidents drive up costs, damage reputations and lower patient satisfaction scores. For instance, if a patient falls off a system's table after being sedated and is badly injured, it can result in significant repercussions for the provider. This type of scenario is rare, but still causes concern for health systems nationwide.

Here are a few observations on cardiovascular ultrasound advances I made while attending the 2015 American Society of Echocardiography (ASE) annual meeting in June:
Toshiba, CT-angiography, hybrid OR

All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce dose and enhance visualization in the cath lab. The vendors have tailored their systems into various models for specific specialties and at various price points depending on the degree of functionality. Most vendors also offer software to enhance visualization of stents and other devices.

DC Devices Inc. announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD). The IASD is a transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).

Subscribe to
Ā© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now